Abstract
A preliminary study of the distribution of the 99mTc complex of hexamethylpropylene amine oxime (HM-PAO) in 12 patients with brain neoplasms before, during, and after radiotherapy has been performed. Untreated brain tumors were found to exhibit a range of 99mTc-HM-PAO uptake, varying from areas of markedly increased isotope activity to photopenic areas, when compared to normal brain tissue. A ratio of 99mTc-HM-PAO tumor uptake to contralateral normal tissue uptake was calculated prior to and during radiotherapy. This ratio tended to return towards unity in lesions responding to therapy. A predictable alteration in whole brain 99mTc-HM-PAO uptake during radiotherapy was not demonstrated. Unlike the radiolabeled amines, 99mTc-HM-PAO localizes in primary tumors, probably indicating that its uptake mechanism is independent of non specific amine receptors. 99mTc-HM-PAO may be useful in the study of brain tumor physiology and response to therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen A, Holm S, Vorstrup S (1985) Tomographic brain imaging using SPECT and a new Tc99m-labeled oxime HMPAO. Eur J Nucl Med 11:A5(A3)
Beaney RP (1984) Positron Emission Tomography in the Study of Human Tumors. Semin Nucl Med 14:324–341
Blasberg RG, Groothuis DR (1986) Chemotherapy of Brain Tumors: Physiological and Pharmacokinetic Considerations. Semin Oncol 13:70–82
Brooks DJ, Beaney RP, Thomas DGT (1986) The Role of Positron Emission Tomography in the Study of Cerebral Tumors. Semin Oncol 13:83–87
Creutzig H, Schober O, Gielow P, Friedrich R, Becker H, Dietz H, Hundeshagen H (1986) Cerebral Dynamics of N-Isopropyl-(I-123) p-iodoamphetamine. J Nucl Med 27:178–183
Hammersley PAG, McCready VR, Babich JW, Coghlan G (1987) Tc-99m HMPAO as a tumor blood flow agent. Eur J Nucl Med 13:90–94
Hill TC, Holman BL, Lovett R, O'Leary DH, Front D, Magistretti P, Zimmerman R, Moore S, Clouse ME, Wu JL, Lin TH, Baldwin RM (1982) Initial Experience with SPECT (Single Photon Emission Computerised Tomography) of the Brain using N-Isopropyl I-123 p-iodoamphetamine: Concise Communication. J Nucl Med 23:191–195
Hoffman TJ, McKenzie EH, Volkert WA, Laughlin MH, Holmes RA (1986) Validation of Tc-99m-d,l-Hexamethyl Propylene Amine Oxime (Tc-99m-d,l-HM-PAO) As a Regional Cerebral Blood Flow Agent: A Microsphere Study. J Nucl Med 27:1050 (abstr.)
Holman BL, Hill TC, Polak, JF (1984) Cerebral Perfusion imaging with Iodine-123 labeled amines. Arch Neurol 41:1060–1063
Kung HF, Tramposch KM, Blau M (1983) A New Brain Perfusion Imaging Agent: [I-123] HIPDM: N,N,N′-Trimethyl-N′[2-Hydroxy-3-Methyl-5-Iodobenzyl]-1, 3-Propanediamine. J Nucl Med 24:66–72
LaFrance ND, Wagner HN, Whitehouse P, Corley E, Duelfer T (1981) Decreased Accumulation of Isopropyliodoamphetamine (I-123) in Brain Tumors. J Nucl Med 22:1081–1083
Langen KJ, Herzog H, Kuwert J, Roosen N, Rota E, Wieler H, Kiwit J, Bock WJ, Feinendgen LE (1987) Tomographic studies of RCBF with, Tc-99m-HM-PAO SPECT in patients with primary brain tumors: Comparison with continuous inhalation of CO-15-O and PET. J Nucl Med 28:591 (abstr.)
Levin VA, Landahl HD, Patlak CS (1981) Drug Delivery to CNS Tumors. Cancer Treat Rep [Suppl. 2] 65:19–25
Lindegaard MW, Skretting A, Hager B, Watne, K, Lindegaard KF (1986) Cerebral and Cerebellar uptake of Tc-99m-(d,l)-hexamethyl-propylene amine oxime (HMPAO) in patients with brain tumor studied by single photon emission computerized tomography. Eur J Nucl Med 12:417–420
Nowotnik, DP, Canning LR, Cumming SA (1985) Development of a Tc-99m-labeled radiopharmaceutical for cerebral blood flow imaging. Nucl Med Comm 6:499–506
Shapiro WR, Shapiro JR (1986) Principles of Brain Tumor Chemotherapy. Semin Oncol 13:56–69
Sharp P, Gemmell H, Cherryman G, Besson J, Crawford J, Smith F (1986a) Application of Iodine-123-labeled isopropylamphetamine imaging to the Study of Dementia. J Nucl Med 27:761–768
Sharp PF, Smith FW, Gemmell HG, Lyall D, Evans NTS, Gvozdanovic D, Davidson J, Tyrrell DA, Pickett RD, Neirinckx RD (1986b) Technetium-99m HMPAO Stereoisomers as Potential Agents for Imaging Regional Cerebral Blood Flow: Human Volunteer Studies. J Nucl Med 27:171–177
Spreafico G, Cammelli F, Gadola G, Nicola G, Zancaner F, Tonnarelli G, Sala E, Freschi R (1987) Initial experience with SPECT of the brain using Tc-99m-hexamethyl-propyleneamine oxime (Tc-99m-HMPAO) Eur J Nucl Med 12:557–559
Tannock IF (1979) The Relationship Between Cell Proliferation and the Vascular System in a Transplanted Mouse Mammary Tumor. Br J Cancer 22:258–273
Warren BA (1979) The Vascular Morphology of Tumors. In: Peterson HI (ed) Tumor Blood Circulation; Angiogenesis Vascular Morphology and Blood Flow of, Experimental and Human Tumors. CRC Press, Boca Raton, Florida, pp 1–43
Winchell HS, Baldwin, RM, Lin TH (1980a) Development of I-123-labeled Amines for Brain Studies: Localization of I-123 Iodophenylalkyl Amines in Rat Brain. J Nucl Med 21:940–946
Winchell HS, Horst WD, Braun L, Oldendorf WH, Hattner R, Parker H (1980b) N-Isopropyl-[I-123]p-Iodoamphetamine: Single Pass Brain Uptake and Washout; Binding to Brain Synaptosomes and Localization in Dog and Monkey Brain. J Nucl Med 21:947–952
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Babich, J.W., Keeling, F., Flower, M.A. et al. Initial experience with Tc-99m-HM-PAO in the study of brain tumors. Eur J Nucl Med 14, 39–44 (1988). https://doi.org/10.1007/BF00252617
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00252617